

PRODUCT INFORMATION

Anti-Guselkumab antibody

Anti-Guselkumab is a chimeric rabbit/mouse antibody targeting the human therapeutic antibody Guselkumab. It has rabbit variable domains and mouse constant domains, and primarily binds to free Guselkumab in samples.

Article number	M9262
Product group	Recombinant Antibody
Technique	ELISA

AntiBodyChain
www.antibodychain.com
order.handling@antibodychain.com
+31(0) 43 2010 660
Wim Duisenbergplantsoen 31
6221SE
Maastricht

Technical information sheet

Plesmanlaan 125
1066 CX Amsterdam
P.O. Box 9190
1006 AD Amsterdam
The Netherlands

Anti-Guselkumab antibody **M9262**

For research use only

Application

Anti-Guselkumab is a chimeric rabbit/mouse anti-idiotypic antibody that specifically targets the human therapeutic antibody Guselkumab. The antibody consists of rabbit variable domains and mouse constant domains. The recombinant antibody binds mainly to free Guselkumab in samples.

Guselkumab is a human IgG1/lambda antibody, recognising the p19 subunit of interleukin-23 (IL-23), and thereby blocks the IL-23 signaling pathway.^(1, 2)

Anti-Guselkumab antibody has been evaluated in ELISA, other techniques need to be validated by the user. It is recommended to test the antibody by titration of the product in the used technique, using appropriate negative/positive controls.




Figure 1: Titration of Guselkumab to create a pharmacokinetic (PK) curve in bridging ELISA. Anti-Guselkumab antibody was used as capture (0.25 µg/ml) and detection (0.125 µg/ml) antibody in sandwich assay format, as described previously.⁽³⁾ GSK= Guselkumab

References

- 1 Nogueira M, Torres T. Guselkumab for the treatment of psoriasis – evidence to date. *Drugs Context*. 2019; **8**.
- 2 European Medicines Agency (EMA). Tremfya (guselkumab). <https://www.ema.europa.eu/en/medicines/human/EPAR/tremfya>. 2022.
- 3 Großrichter-Wagener C, Kos D, van Leeuwen A, Dijk L, Jeremiasse J, Loeff FC et al. Biased anti-idiotypic response in rabbits leads to high-affinity monoclonal antibodies to biologics. *MAbs* 2020; **12**. PMID:32887534.